Mrinal Gounder, MD

Memorial Sloan Kettering Cancer Center

Poster(s):

• (P 24) COMPREHENSIVE ANALYSIS OF THE GENOMIC LANDSCAPE AND CLINICAL BEHAVIOR IN GIST USING NEXT GENERATION SEQUENCING (NGS, MSK-IMPACT)

• (P 172) PHASE 2 RESULTS FROM THE RINGSIDE PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS

• (P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST

• (P 188) IMPACT OF NIROGACESTAT ON FUNCTIONAL STATUS IN PATIENTS WITH DESMOID TUMORS: RESULTS FROM THE PHASE 3 DEFI STUDY

• (P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES

• (P 549) DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF AL102 FOR TREATMENT OF PROGRESSING DESMOID TUMORS: THE RINGSIDE PHASE 3 STUDY DESIGN